Neovascular Age-Related Macular Degeneration Treatments
|NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENTS|
|VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS|
|brolucizumab-dbll||Beovu||6mg/0.05mL||soln for intravitreal inj||6mg (0.05mL) once monthly (approx. 25–31 days) for the 1st 3 doses, followed by 6mg (0.05mL) once every 8–12wks|
|pegaptanib sodium||Macugen||0.3mg per prefilled syringe||soln for intravitreal inj||0.3mg once every 6wks|
|ranibizumab||Lucentis||6mg/mL (0.3mg), 10mg/mL (0.5mg)||soln for intravitreal inj||0.5mg (0.05mL of 10mg/mL) once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3mos after 4 monthly doses (less effective). Monitor regularly.|
|Byooviz1||10mg/mL (0.5mg)||soln for intravitreal inj|
|Cimerli1||6mg/mL (0.3mg), 10mg/mL (0.5mg)||soln for intravitreal inj|
soln for intravitreal implant or intravitreal inj
|2mg (0.02mL of 100mg/mL) continuously delivered via implant. Refill every 24wks (approx. 6mos). Supplemental treatment: 0.5mg (0.05mL of 10mg/mL) intravitreal inj into the affected eye while implant is in place, as clinically needed.|
|VEGF INHIBITOR + ANGIOPOIETIN-2 (ANG-2) INHIBITOR|
|faricimab-svoa||Vabysmo||120mg/mL||soln for intravitreal inj||6mg (0.05mL) once every 4wks (approx. every 28 ± 7 days, monthly) for the 1st 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12wks later to determine whether to give a 6mg (0.05mL) dose on one of the following 3 regimens: (1) Weeks 28 and 44; (2) Weeks 24, 36 and 48; or (3) Weeks 20, 28, 36 and 44.|
|VEGF INHIBITOR + HUMAN IgG1|
|aflibercept||Eylea||2mg/0.05mL||soln for intravitreal inj||2mg (0.05mL) once every 4wks (approx. 28 days, monthly) for the 1st 12wks (3mos), followed by 2mg (0.05mL) once every 8wks (2mos); some may need the monthly dosing after the 1st 3mos. May also treat with 1 dose every 12wks after one year of successful therapy (not as effective); assess regularly.|
|verteporfin||Visudyne3||15mg per vial||pwd for IV infusion after reconstitution and dilution||Infuse over 10mins at a rate of 3mL/min. Usual dose: 6mg/m2. After infusion, the second step is activation of verteporfin with light from a nonthermal diode laser. Reevaluate every 3mos and if choroidal neovascular leakage is detected on fluorescein angiography, therapy should be repeated.|
1 Biosimilar to Lucentis.
2 In patients who have previously responded to at least 2 intravitreal injections of a VEGF inhibitor.
3 Consider for wet AMD patients with persistent intraocular fluid leakage, including anti-VEGF nonresponders.
Not an inclusive list of medications and/or official indications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.